Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors
Arthritis Care & Research · 2026
DOI: 10.1002/acr.25691 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, 2026. Verfasst von Madeline L O'Sullivan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Salt Lake City VA and University of Utah. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Immune Checkpoint Inhibitors, Veterans, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: NIH HHS, U.S. Department of Veterans Affairs, CSRD VA.
Abstract (Originalsprache)
Objective
This investigation compared all‐cause and cause‐specific mortality in patients with and without rheumatoid arthritis (RA) in the Veterans Health Administration (VHA) following immune checkpoint inhibitor (ICI) cancer treatment.
Methods
Veterans with RA and a control set of Veterans without RA who were matched on age, sex, and year of Veterans Affairs enrollment and had received an ICI were identified. All‐cause and cause‐specific mortality were obtained. Survival from the time of ICI initiation was evaluated using Cox models, Kaplan‐Meier curves, and log rank testing.
Results
There were 301 patients with RA and 2,114 controls without RA treated with an ICI. The majority of the participants were white, male, and current/former smokers. Lung cancer was the most common malignancy (51.2%), pembrolizumab was the most frequently used ICI (43.9%), and most patients received ICI monotherapy (97.1%). Cox proportional hazard ratio comparison of all‐cause mortality in patients with RA to controls without RA was 1.08 (95% confidence interval [CI] 0.94–1.25) for the crude analysis and 1.09 (95% CI 0.94–1.25) for the adjusted analysis. Cause of death was similar in the two groups, most frequently neoplasm in 93.0% and 90.9% for RA and non‐RA groups, respectively ( P = 0.737). Deaths due to infection were rare in both groups (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Salt Lake City VA and University of Utah.
- Puget Sound VA Medical Center, Seattle, Washington.
- University of Utah, Salt Lake City.
- VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha.
- Corporal Michael J. Crescenz VA and University of Pennsylvania, Philadelphia.
ORCID-Profile: Grant W Cannon, Brian C Sauer, Jessica A Walsh, Bryant R England, Ted R Mikuls
Förderung
- NIH HHS
- U.S. Department of Veterans Affairs
- CSRD VA
- U.S. Department of Defense
- Western Institute for Veterans Research
- National Institutes of Health
Zitieren
APA
O'Sullivan, M. L., Cannon, G. W., Sauer, B. C., Rojas, J., Kunkel, G. A., Walsh, J. A., Patel, S., Roul, P., Baker, J. F., England, B. R., Mikuls, T. R., & Braaten, T. J. (2026). Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors. Arthritis Care & Research. https://doi.org/10.1002/acr.25691
Vancouver
O'Sullivan ML, Cannon GW, Sauer BC, Rojas J, Kunkel GA, Walsh JA, et al. Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors. Arthritis Care & Research. 2026. doi:10.1002/acr.25691
BibTeX
@article{OSullivan2026,
author = {O'Sullivan, Madeline L and Cannon, Grant W and Sauer, Brian C and Rojas, Jorge and Kunkel, Gary A and Walsh, Jessica A and Patel, Shardool and Roul, Punyasha and Baker, Joshua F and England, Bryant R and Mikuls, Ted R and Braaten, Tawnie J},
title = {Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors},
journal = {Arthritis Care & Research},
year = {2026},
doi = {10.1002/acr.25691}
}
EUVIMED